Latest Period
Q2 2026
Security Snapshot
Zentalis Pharmaceuticals, Inc. - Common Stock, $0.001 par value per share (ZNTL) Institutional Ownership
CUSIP: 98943L107
13F Institutional Holders and Ownership History from Q2 2020 to Q2 2026
Institutions Reporting
113
Shares (Excl. Options)
47,367,469
Price
$4.85
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, $0.001 par value per share
- Symbol
- ZNTL on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 47,367,469
- Total 13F value
- $228,855,010
- Portfolio coverage rank
- 0%
- Share change
- +4,503,719
- Value change
- +$25,896,230
- Number of holders
- 113
- Shares outstanding
- 94,920,069
- SEC-reported price per share
- $4.33
- Insider filing price
- $4.33
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- ZNTL - Zentalis Pharmaceuticals, Inc. - Common Stock, $0.001 par value per share is tracked under CUSIP 98943L107.
- 113 institutions reported positions in Q2 2026.
- 9 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 100 to 113 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $101,671,381 to $228,855,010.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 113 institutions filings for Q2 2026.
Security key
98943L107
Latest holder period
Q2 2026
13F holders
113
13D/G owners
9
CIK / CUSIP context first
Open Q2 2026 holders
ZNTL full holder history
Zentalis Pharmaceuticals, Inc. SEC filings
Zentalis Pharmaceuticals, Inc. company facts
Zentalis Pharmaceuticals, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 98943L107:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
9
Security
ZNTL
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| WALTERS GROUP | 19% | -4.5% | $77,268,733 | +$18,770,550 | 17,844,973 | +32% | Walters William T | 14 Aug 2026 |
| Walters William T | 9.9% | +8.9% | $10,081,500 | +$786,500 | 7,050,000 | +8.5% | Walters William T | 29 Jan 2025 |
| 5AM Opportunities II (GP), LLC | 6.4% | $7,257,856 | 4,838,571 | Andrew J. Schwab | 18 Dec 2025 | |||
| BlackRock, Inc. | 5.2% | +150% | $17,997,933 | +$10,173,316 | 3,710,914 | +130% | BlackRock, Inc. | 30 Jun 2026 |
| Squadron Capital Management LLC | 5.1% | $9,376,095 | 3,676,900 | Squadron Master Fund LP | 24 Feb 2026 | |||
| VANGUARD GROUP INC | 4.6% | $4,677,873 | 3,271,240 | The Vanguard Group | 31 Dec 2024 | |||
| BARCLAYS PLC | 3.2% | -43% | $9,868,110 | -$6,880,608 | 2,263,328 | -41% | Barclays PLC | 30 Jun 2026 |
| MILLENNIUM MANAGEMENT LLC | 1.3% | -80% | $1,272,555 | -$4,059,076 | 902,521 | -76% | Millennium Management LLC | 30 Sep 2025 |
| FMR LLC | 0.2% | $251,484 | 175,863 | FMR LLC | 29 Nov 2024 |
As of 30 Jun 2026, 113 institutional investors reported holding 47,367,469 shares of Zentalis Pharmaceuticals, Inc. - Common Stock, $0.001 par value per share (ZNTL). This represents 50% of the company’s total 94,920,069 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
42%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| 5AM Venture Management, LLC | 4.2% | 3,947,913 | 0% | 6.7% | $19,147,378 |
| BlackRock, Inc. | 4% | 3,753,525 | +196% | 0% | $18,204,597 |
| Squadron Capital Management LLC | 3.9% | 3,700,000 | +1.9% | 6.1% | $17,945,000 |
| TWO SIGMA INVESTMENTS, LP | 3.2% | 3,024,936 | +2.3% | 0.01% | $14,670,940 |
| VANGUARD CAPITAL MANAGEMENT LLC | 3% | 2,835,669 | +23% | 0% | $13,752,995 |
| ACADIAN ASSET MANAGEMENT LLC | 2.8% | 2,681,900 | -5.8% | 0.02% | $12,995,000 |
| CITADEL ADVISORS LLC | 2.4% | 2,298,403 | +33% | 0.01% | $11,147,254 |
| RENAISSANCE TECHNOLOGIES LLC | 1.7% | 1,609,078 | -17% | 0.01% | $7,804,028 |
| Opaleye Management Inc. | 1.5% | 1,412,656 | 0% | 0.62% | $6,851,382 |
| ORBIMED ADVISORS LLC | 1.5% | 1,390,576 | 0.13% | $6,744,294 | |
| Decheng Capital LLC | 1.4% | 1,323,327 | 0% | 0.88% | $6,418,136 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.4% | 1,284,117 | +107% | 0% | $6,229,699 |
| BANK OF AMERICA CORP /DE/ | 1.2% | 1,114,650 | -1.6% | 0% | $5,406,053 |
| Ishara Investments LP | 1.1% | 1,025,000 | -17% | 3.8% | $4,971,250 |
| PRIMECAP MANAGEMENT CO/CA/ | 1% | 957,420 | 0% | 0% | $4,643,487 |
| Pfizer Inc | 1% | 953,834 | 0% | 2.3% | $3,853,489 |
| Soleus Capital Management, L.P. | 1% | 950,000 | 0.16% | $4,607,500 | |
| STATE STREET CORP | 0.93% | 887,416 | +255% | 0% | $4,303,968 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 0.85% | 808,548 | +124% | 0% | $3,921,458 |
| Connor, Clark & Lunn Investment Management Ltd. | 0.8% | 758,033 | -4.3% | 0.01% | $3,676,460 |
| MILLENNIUM MANAGEMENT LLC | 0.7% | 664,281 | -48% | 0% | $3,221,763 |
| ADAR1 Capital Management, LLC | 0.69% | 652,750 | +351% | 0.15% | $3,165,838 |
| MARSHALL WACE, LLP | 0.62% | 591,473 | +51% | 0% | $2,868,644 |
| Qube Research & Technologies Ltd | 0.61% | 574,806 | -9.8% | 0% | $2,787,809 |
| D. E. Shaw & Co., Inc. | 0.58% | 546,566 | -63% | 0% | $2,650,845 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
25
Latest
Q2 2026
Rows shown
1-25 of 25
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 47,367,469 | $228,855,010 | +$25,896,230 | $4.85 | 113 |
| 2026 Q1 | 43,560,789 | $101,671,381 | +$8,469,477 | $2.34 | 100 |
| 2025 Q4 | 40,517,312 | $54,747,323 | -$20,028,376 | $1.35 | 85 |
| 2025 Q3 | 52,751,330 | $79,656,235 | -$3,936,309 | $1.51 | 96 |
| 2025 Q2 | 55,655,238 | $64,573,024 | -$4,209,380 | $1.16 | 115 |
| 2025 Q1 | 58,450,755 | $92,928,558 | -$20,527,901 | $1.59 | 131 |
| 2024 Q4 | 64,418,043 | $195,184,400 | -$24,736,255 | $3.03 | 141 |
| 2024 Q3 | 70,964,067 | $261,154,970 | -$21,635,153 | $3.68 | 133 |
| 2024 Q2 | 76,565,937 | $313,165,477 | -$54,359,485 | $4.09 | 142 |
| 2024 Q1 | 85,290,558 | $1,344,227,610 | +$67,005,140 | $15.76 | 140 |
| 2023 Q4 | 81,068,438 | $1,228,198,230 | -$21,970,408 | $15.15 | 118 |
| 2023 Q3 | 80,197,042 | $1,608,751,464 | -$51,643,382 | $20.06 | 136 |
| 2023 Q2 | 82,228,758 | $2,319,672,532 | +$442,954,370 | $28.21 | 131 |
| 2023 Q1 | 67,021,594 | $1,152,767,927 | +$44,945,526 | $17.20 | 108 |
| 2022 Q4 | 64,360,813 | $1,296,145,033 | +$105,231,060 | $20.14 | 106 |
| 2022 Q3 | 58,811,479 | $1,273,846,102 | -$54,003,564 | $21.66 | 116 |
| 2022 Q2 | 58,254,677 | $1,636,896,016 | +$359,446,058 | $28.10 | 115 |
| 2022 Q1 | 44,437,538 | $2,050,628,439 | +$49,057,461 | $46.14 | 123 |
| 2021 Q4 | 42,987,158 | $3,611,907,936 | +$90,022,119 | $84.06 | 134 |
| 2021 Q3 | 41,250,292 | $2,749,252,645 | +$115,288,600 | $66.64 | 114 |
| 2021 Q2 | 39,699,603 | $2,112,018,735 | +$205,833,024 | $53.20 | 117 |
| 2021 Q1 | 36,327,192 | $1,576,156,109 | -$55,960,381 | $43.39 | 93 |
| 2020 Q4 | 37,299,066 | $1,937,340,198 | +$309,645,949 | $51.94 | 104 |
| 2020 Q3 | 31,635,340 | $1,033,195,545 | +$169,604,096 | $32.69 | 65 |
| 2020 Q2 | 26,858,048 | $1,282,608,905 | +$1,282,608,902 | $48.02 | 61 |